Xlife Sciences AG / Key word: Mergers & Acquisitions/Takeover
VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline
29-Dec-2023 / 17:45 CET/CEST
Release of an ad hoc.
Xlife Sciences AG Key word Mergers & AcquisitionsTakeover VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline 29Dec2023 1745 CETCEST Release of an ad hoc announcement pursuant to
The new CFO brings extensive experience in finance and business development at life science, pharma and technology companies.HEIDELBERG, Germany, March 22, 2022 / B3C newswire / Torsten Buergermeister has been appointed Chief Financial Officer (CFO) of VERAXA Biotech, based in Heidelberg, Germany. Buergermeister.
Lars Hufnagel will be responsible for advancing VERAXA’s antibody screening and ADC technologies by further developing its droplet-based microfluidic screening technology.HEIDELBERG, Germany, March 14, 2022 / B3C newswire / Dr. Lars Hufnagel has been appointed Chief Technical Officer (CTO) of VERAXA Biotech, base.
Search jobs VERAXA Biotech and Quadira Biosciences Enter Partnership on ADC Development
HEIDELBERG, Germany and ZUG, Switzerland, June 14, 2021 / B3C newswire / VERAXA Biotech GmbH (former Velabs Therapeutics GmbH), a leading company in innovative ADC engineering and functional antibody screening, announced today that it has entered into a partnership agreement with Quadira Biosciences AG, Zug, Switzerland, to jointly develop a suite of novel ADCs for the treatment of oncological conditions. The collaboration will leverage both the advantages of VERAXA s advanced and proprietary position-true click-chemistry-based drug conjugation technology in combination with Quadira’s superior 3D cellular assay and assessment systems. The agreement provides that VERAXA will be entitled to upfront payments and royalties from the worldwide sale of products resulting from the collaboration. Further details of the agreement were not disclosed.